Centogene

WKN: A2PUCU ISIN: NL0014040206 Mehr zu "Centogene"

Börse
Nasdaq

11,44 USD

+8,54 % +0,90

Geld (Stk.) 11,120 (200)
Brief (Stk.) 11,710 (200)
Spread 5,038
Geh. Stück 19.583 Stk
Eröffnung 10,540
Vortag 10,540
52 Wochen Hoch 15,590
52 Wochen Tief 7,800

Stand: 27.02.2020 - 23:20:00 Uhr

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Kursdaten: k.A.

Anzeige
Alles für nur 4 Euro pro Order. Dauerhaft.
Smartbroker

Geld/Brief Kurse

Börse Geld Brief Zeit Volumen Kurs
Frankfurt 10,600 10,900 1582791784 27.02.20 0 10,90 EUR
Berlin 10,400 11,300 1582825348 27.02.20 0 11,00 EUR
Düsseldorf 10,500 11,200 1582788769 27.02.20 0 11,00 EUR
München 10,600 11,100 1582816767 27.02.20 0 10,90 EUR
Stuttgart 8,550 3.980,000 1582811636 27.02.20 0 10,90 EUR
Nasdaq 11,120 11,710 1582842000 27.02.20 19.583 11,44 USD
AMEX 0,000 0,000 1580432400 31.01.20 0 10,10 USD
Tradegate 10,000 10,800 1582838794 27.02.20 3.645 10,40 EUR
Lang & Schwarz 10,300 10,400 1582839836 27.02.20 567 10,35 EUR
Gettex 9,850 10,900 1582836180 27.02.20 0 10,90 EUR
Baader Bank 9,700 10,900 1582836160 27.02.20 0 10,43 EUR

Realtime / Verzögert

Neueste Kommentare (16)

Neu laden

Alle Kommentare Neu laden

Peppihro

Peppihro vom 13.02.20 07:54 Uhr

Contact Us  Home Company 02/12/2020 CENTOGENE Biobank Receives Accreditation from College of American Pathologists State-of-the-art Biorepository in Rostock, Germany is the first CAP-accredited repository outside the U.S. Cambridge, MA, USA & Rostock, Germany February 12, 2020 – (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists (CAP). The CAP’s Biorepository Accreditation Program is designed to improve the quality and consistency of biorepositories through requirements for standardization that will result in high-quality human specimens and genetic materials that can be used to support research. “CENTOGENE is proud to be the first biorepository to receive this accreditation from the CAP outside of the U.S., which recognizes our continued commitment to the highest quality standards, our pharmaceutical and scientific collaboration partners,” said Ellen Karges, VP Regulatory Compliance & Quality Management. “CENTOGENE reached another milestone by successfully completing their Biorepository Accreditation in partnership with CAP (College of American Pathologists). As the first Biorepository to receive this accreditation from CAP within Europe, we provide further proof of our commitment to the highest quality for our patients, pharmaceutical and scientific collaboration partners. Furthermore, CENTOGENE maintains the ethical handling of samples for the developing of diagnostic tools and supporting the development of new treatments that will have a positive impact on patients with rare diseases.” About CAP CAP is the world’s largest organization of board-certified pathologists and the leading provider of laboratory accreditation and proficiency testing programs. CAP, the first in the industry to offer an accreditation program for biorepositories, based the program on the principles of its Laboratory Accreditation Program. The accreditation process, a three-year accreditation cycle, includes on-site inspection, desk review, and optional education modules and gap assessment – designed to ensure the highest standard of patient care and application of best practice. For more information on CAP, please visit the following website: https://www.cap.org/

Q

Quip vom 22.01.20 19:11 Uhr

Hallo, was macht das unternehmen interessant? LG

Porakelix

Porakelix vom 09.01.20 16:54 Uhr

Bin seit Dezember dabei und habe zwischendurch nachgelegt. Finde das Unternehmen interessant und sehe auf lange Sicht viel Potential. Viel Glück allen investierten 🍀

Y

Youngbank vom 16.12.19 11:43 Uhr

Lieber centogene oder doch biontech?

j

julia180676 vom 09.12.19 22:11 Uhr

Ja den kenne ich. Kann es nicht deuten. Seit dem keine News mehr

d

dontlistentowhatfranksays5c5f80556ca07 vom 09.12.19 21:35 Uhr

Könnte was mit dem neuen Herausgeber der Berliner Zeitung, dessen Stasi-Vergangenheit und der von ihm angestoßenen positiven Berichterstattung in der Berliner Zeitung zu Centogene zu tun haben, wo er 3,27 % der Anteile halte. Hier ein 3 Wochen alter Artikel zum Thema aus eben jener Berliner Zeitung: https://www.berliner-zeitung.de/politik-gesellschaft/centogene-und-die-berliner-zeitung-li.1553

R

RaZuPaltuFF vom 09.12.19 20:33 Uhr

Keine ahnung

Alle Kommentare Neu laden

Grundlegende Daten zur Centogene Aktie

Finanzdaten 2016 2017 2018 2019 2020 2021
Ergebnis je Aktie (bereinigt) - - - - - -
Cashflow - - - - - -
Eigenkapitalquote - - - - - -
Verschuldungsgrad - - - - - -
Eigenkapitalrendite - - - - - -
Gesamtkapitalrendite - - - - - -
EBITDA - - - - - -
EBIT - - - - - -
Fundamentaldaten 2016 2017 2018 2019 2020 2021
Dividendenrendite - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - -
Dividende je Aktie - - - - - -
Bilanzdaten 2016 2017 2018 2019 2020 2021
Netto-Provisionsüberschuss - - - - - -
Umsatzerlöse - - - - - -
Ergebnis vor Steuern - - - - - -
Steuern - - - - - -
Ausschüttungssumme - - - - - -
Nettoverzinsung - - - - - -
Zinsertrag - - - - - -
Gesamtertrag - - - - - -

Centogene

Börsennotierung

Marktkapitalisierung
- EUR
Anzahl der Aktien
- Stück